BIOTECHNOLOGY SPOTLIGHT NOW SHINES ON CHIRON
In the rarefied world of biotechnology, the Chiron Corporation has always had the respect of its peers. Now, it is also starting to bask in the limelight long enjoyed by such older and larger competitors as Genentech Inc. and the Cetus Corporation. This week, Chiron and Ciba-Geigy Ltd., the Swiss-based pharmaceutical giant, announced an ambitious joint venture to develop a series of genetically engineered vaccines for AIDS, herpes and malaria, among other diseases. And this summer, Chiron received the first Food and Drug Administration approval of such a vaccine for human use. The approval of the drug for hepatitis B, a potentially deadly liver disease, made the five-year-old company one of the few biotech enterprises with a product to sell.